• Guardant Health's Tests Are Pioneering a Shift in Precision Oncology

  • Oct 17 2024
  • Length: 43 mins
  • Podcast

Guardant Health's Tests Are Pioneering a Shift in Precision Oncology

Listen for free

View show details

  • Summary

  • “Our liquid biopsy test alone, we estimate one in four cancer patients in the US are getting it,” Helmy Eltoukhy, cofounder and co-CEO of Guardant Health, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Eltoukhy joins BI analyst Jonathan Palmer to discuss the underpinnings of the liquid biopsy revolution and how Guardant has stuck to its technology road map since its founding in 2012, launching products in each of the three major market categories. The conversations also covers the company’s recent approval of its Shield colorectal screening test as well as many of the scientific and commercial challenges to standing up the business.

    See omnystudio.com/listener for privacy information.
    Show More Show Less
Hygiene & Healthy Living Economics Personal Finance
Show More Show Less
activate_samplebutton_t1

What listeners say about Guardant Health's Tests Are Pioneering a Shift in Precision Oncology

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com.au reviews

Amazon Reviews
No Reviews are Available
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.